Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

H020: Single-Arm Open Label, Pilot Study of CCR5/CCR2 Inhibitor Cenicriviroc (CVC) for HIV Associated Neurocognitive Disorder (HAND)

Next Previous
Trial Profile

H020: Single-Arm Open Label, Pilot Study of CCR5/CCR2 Inhibitor Cenicriviroc (CVC) for HIV Associated Neurocognitive Disorder (HAND)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cenicriviroc (Primary)
  • Indications Cognition disorders
  • Focus Therapeutic Use

    • Most Recent Events

    • 25 May 2018 New trial record
    • 16 May 2018 Primary endpoint (Change from baseline to week 24 in Neuropsychological Performance utilizing a battery of neuropsychological tests (domain-specific:Psychomotor Speed, Visuospatial Reasoning, Executive Function, Learning and Memory, Gross Motor)) has not been met, according to results published in the JAIDS:Journal of acquired immune deficiency syndromes.
    • 16 May 2018 Primary endpoint (Change from baseline to week 24 in Neuropsychological Performance utilizing a battery of neuropsychological tests (global NPZ and cognitive domains of attention and working memory)) has been met, according to results published in the JAIDS:Journal of acquired immune deficiency syndromes.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top